# Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

> **NCT03059381** · — · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 519 (actual)

## Conditions studied

- Partial Seizures (With or Without Secondary Generalized Seizures)
- Primary Generalized Tonic-clonic Seizures

## Interventions

- **DRUG:** Fycompa

## Key facts

- **NCT ID:** NCT03059381
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-01
- **Primary completion:** 2021-03-21
- **Final completion:** 2021-03-21
- **Target enrollment:** 519 (ACTUAL)
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059381, "Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03059381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*